Peer-review started: September 1, 2016
First decision: October 26, 2016
Revised: November 12, 2016
Accepted: December 16, 2016
Article in press: December 19, 2016
Published online: March 28, 2017
Processing time: 205 Days and 23.7 Hours
Alcohol is a well-recognized teratogen that can cause variable physical and behavioral effects on the fetus. Alcohol use and abuse during pregnancy is one of the major health and societal problems and has been linked to a wide range of birth defects in the offspring collectively termed as fetal alcohol spectrum disorder (FASD). The severity of abnormalities may depend on a number of factors that include the amount, the frequency, the period during gestation and the route of alcohol administration. The current knowledge about the neurobiological basis of FASD is limited. However, recent studies have suggested that the membrane-derived lipids especially bioactive endogenous cannabinoids (eCB) such as arachidonyl ethanolamide and 2-arachidonyl glycerol resulting from alcohol exposure, may play a significant role in modulating neurophysiological and neurobehavioral effects in chronic alcohol exposed adult animals. Based on these findings and on reported studies on the role of eCB signaling in neurodevelopment and behavior, it is speculated that the eCB signaling may play a critical role in fetal alcohol syndrome and FASD-related behavioral effects. The current discussion will touch upon some of the mechanistic explanations about the role of eCB signaling system in FASD and provide further guidance for future direction.
Core tip: Drinking during pregnancy leads to severe neurobiological consequences in the fetus and results in a variety of morphological and neurobehavioral abnormalities including mental retardation. One of the promising neurobiological mechanisms that can explain fetal alcohol spectrum disorder as discussed in this editorial is that of the possible role of alcohol-induced alteration in the levels of bioactive endogenous cannabinoids (eCBs) that are derived from membrane lipids and eCB signaling. Further studies exploring dietary supplementation with unsaturated fatty acids that can regulate the levels of the eCBs and testing of the drugs targeted against the eCB signaling, may have significant therapeutic value.